Report ID: 10294006 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
REPORT HIGHLIGHT
Tumor ablation market was valued at USD 897.1 million by 2017, growing with 10.9% CAGR during the forecast period, 2018-2025.
Tumor ablation is a minimally invasive procedure which is majorly used to treat tumors present in kidney, liver, bone, and lungs. In tumor ablation, tissues are cooled or heated to less than -40°C or more than 60°C using thermal energy. The success rate of complete small liver cancer through this process is more than 85%. This treatment is a good option for those patients who failed during radiotherapy or chemotherapy.
Market Dynamics
The growing number of cancer patients worldwide support industry growth significantly. As per the World Health Organization (WHO), cancer has taken the life of 9.6 million people in 2018. Tumor ablation is quite effective in cases when the abnormal cell is not bigger than 3cms. This technology doesn’t have any side effect and the patient doesn’t require hospitalization. No large incisions are involved in tumor ablation which results in less recovery time.
Excellent growth has been observed in the global market owing to the increasing awareness regarding the benefits of tumor ablation devices over surgical and other conventional techniques. Geriatric population, rise in cancer cases, economical treatment options are some of the other factors to fuel the demand for this technology across the globe. It is anticipated that the tumor ablation market size will reach worth USD 2.10 billion by 2025 with a CAGR of 10.9%.
Product Takeaway
The market is classified into four types namely cryoablation, radiofrequency, microwave and other ablation technologies. Currently, the radiofrequency market is on the rise because of its targeted treatment without causing any damage to surrounding healthy cells. This product segment is accounted for over 35% revenue share of the overall market. Whereas microwave ablation category is anticipated to rise during the study period because of the rise in private funding for the development of this technology coupled with growing adoption by healthcare professionals. In addition, this product segment is gradually picking up the pace owing to the emergence of robot-assisted technique. The global demand for microwave ablation is expected to rise with a CAGR of 15.3% between 2017-2025.
Application Takeaway
Based on application, the industry is bifurcated as liver, breast, lung, prostate, and other types. In terms of market size, liver cancer is accounted for the highest revenue share of the global market. According to the American Institute of Cancer Research (AICR), there were over 840,000 new cases of liver cancer in 2018. Such an increasing disease rate is directing patients’ focus towards this new technique of ablation. On contrary, lung cancer is projected to grow with a strong growth rate in the coming years. The main reason for the growth of this application segment is the rising consumption of alcohol and cigarette.
Regional Takeaway
North America is dominating the tumor ablation market owing to the increasing demand for minimally invasive surgeries. In terms of revenue, North America contributed $360.8 billion in 2017 and it is anticipated that this growth will increase with a CAGR of 10.5% during the forecast period. Asia-Pacific is the rapidly growing region due to the increase in the count of cancer patients, and favorable government support.
Key Vendor Takeaway
Companies like Galil Medical, Misonix, HealthTronics, Covidien plc, Boston Scientific, Medtronic plc, SonaCare Medical, and Neuwave Medical are the key players in this sector. This market has come up with numerous opportunities for vendors and is characterized by the participation of both local and multinational vendors.
Many strategies like new product launch and technological advancements are adopted by these companies to retain their position in the current market. For example, BARRX Medical Inc. is acquired by Covidien plc and this acquisition resulted in goodwill generation for the company. Similarly, Galil Medical has come up with a new family of cryoablation needles namely IcePearl 2.1CX, IceFORCE 2.1 CX. These products launch will add value to the company’s portfolio.
The market size and forecast for each segment and sub-segments has been considered as below:
Historical Year – 2014 & 2016
Base Year – 2017
Estimated Year – 2018
Projected Year – 2025
TARGET AUDIENCE
Traders, Distributors, and Suppliers
Manufacturers
Government Agencies
Regional Agencies
Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MARKET, BY PRODUCT
Cryoablation
Radiofrequency Ablation
Microwave Ablation
MARKET, BY APPLICATION
Liver Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
Bone Metastasis
ENT Cancer
MARKET, BY REGION
North America
U.S.
Canada
Europe
Germany
France
Rest of Europe
Asia Pacific
India
China
Rest of APAC
Rest of the World
Middle East and Africa
Latin America
T
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10294006 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
